TWI350289B - Novel compounds - Google Patents

Novel compounds

Info

Publication number: TWI350289B
Authority: TW; Taiwan
Prior art keywords: novel compounds; novel; compounds
Prior art date: 2004-02-14

Application number

TW094104133A

Other languages

English (en)

Other versions

TW200536537A (en

Inventor

Ivan Leo Pinto

Shahzad Sharooq Rahman

Neville Hubert Nicholson

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-14

Filing date

2005-02-14

Publication date

2011-10-11

2004-02-14 Priority claimed from GB0403282A external-priority patent/GB0403282D0/en

2004-10-22 Priority claimed from GB0423562A external-priority patent/GB0423562D0/en

2004-12-24 Priority claimed from GB0428375A external-priority patent/GB0428375D0/en

2005-02-14 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2005-11-16 Publication of TW200536537A publication Critical patent/TW200536537A/zh

2011-10-11 Application granted granted Critical

2011-10-11 Publication of TWI350289B publication Critical patent/TWI350289B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW094104133A 2004-02-14 2005-02-14 Novel compounds TWI350289B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0403282A GB0403282D0 (en)	2004-02-14	2004-02-14	Chemical compounds
GB0423562A GB0423562D0 (en)	2004-10-22	2004-10-22	Novel compounds
GB0428375A GB0428375D0 (en)	2004-12-24	2004-12-24	Novel compounds

Publications (2)

Publication Number	Publication Date
TW200536537A TW200536537A (en)	2005-11-16
TWI350289B true TWI350289B (en)	2011-10-11

Family

ID=34864831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094104133A TWI350289B (en)	2004-02-14	2005-02-14	Novel compounds

Country Status (25)

Country	Link
US (5)	US7713982B2 (zh)
EP (1)	EP1781657B1 (zh)
JP (2)	JP5001012B2 (zh)
KR (1)	KR101100601B1 (zh)
CN (2)	CN101863888B (zh)
AR (1)	AR047669A1 (zh)
AU (1)	AU2005212816C1 (zh)
BR (1)	BRPI0507604A (zh)
CA (1)	CA2556073C (zh)
CY (1)	CY1114022T1 (zh)
DK (1)	DK1781657T3 (zh)
ES (1)	ES2406732T3 (zh)
HR (1)	HRP20130406T1 (zh)
IL (1)	IL177051A (zh)
MA (1)	MA28357A1 (zh)
MY (1)	MY148937A (zh)
NO (1)	NO337281B1 (zh)
NZ (1)	NZ548496A (zh)
PE (1)	PE20060317A1 (zh)
PL (1)	PL1781657T3 (zh)
PT (1)	PT1781657E (zh)
SG (1)	SG157242A1 (zh)
SI (1)	SI1781657T1 (zh)
TW (1)	TWI350289B (zh)
WO (1)	WO2005077950A2 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ527917A (en) *	1999-11-12	2005-03-24	Biogen Inc	Polycycoalkylpurines as adenosine receptor antagonists
AR039385A1 (es)	2002-04-19	2005-02-16	Astrazeneca Ab	Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004083388A2 (en)	2003-03-14	2004-09-30	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7713982B2 (en) *	2004-02-14	2010-05-11	Smithkline Beecham Corporation	Xanthines with HM74A receptor activity
WO2006060461A1 (en)	2004-12-03	2006-06-08	Schering Corporation	Substituted piperazines as cb1 antagonists
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006124490A2 (en)	2005-05-17	2006-11-23	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en)	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006134040A1 (en) *	2005-06-14	2006-12-21	F. Hoffmann-La Roche Ag	Anthranilic acid derivatives
KR20080019653A (ko)	2005-06-28	2008-03-04	머크 앤드 캄파니 인코포레이티드	나이아신 수용체 효능제, 이를 함유하는 조성물 및치료방법
MX2008001931A (es) *	2005-08-10	2008-03-24	Smithkline Beecham Corp	Derivados de xantina como agonistas selectivos de hm74a.
WO2007087204A2 (en) *	2006-01-20	2007-08-02	Schering Corpooration	Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
ATE469905T1 (de) *	2006-05-23	2010-06-15	Hoffmann La Roche	Pyridopyrimidinonderivate
TW200804383A (en)	2006-06-05	2008-01-16	Astrazeneca Ab	New compounds
AR061625A1 (es) *	2006-06-23	2008-09-10	Incyte Corp	Derivados de purinona como agonistas de hm74a
US7462624B2 (en)	2006-06-23	2008-12-09	Incyte Corporation	Purinone derivatives as HM74a agonists
KR101115891B1 (ko) *	2007-03-23	2012-02-13	에프. 호프만-라 로슈 아게	아자-피리도피리미딘온 유도체
BRPI0922134A2 (pt) *	2008-12-08	2015-08-18	Glaxosmithkline Llc	Compostos
EP2379562A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) *	2011-05-04	2013-01-09	北京工业大学	N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) *	2013-07-29	2015-07-22	上海万巷制药有限公司	8-氯茶碱的制备方法
WO2016119570A1 (zh) *	2015-01-30	2016-08-04	上海珊顿医药科技有限公司	尿酸性或痛风性疾病的预防或治疗
CN104892610B (zh) *	2015-05-27	2016-08-24	福建师范大学	一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) *	2016-03-28	2016-06-01	浙江诚意药业股份有限公司	一种黄嘌呤化合物的制备方法
EP3490579B1 (en)	2016-07-27	2025-09-10	Hartis-Pharma SA	Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) *	2016-11-23	2020-07-24	上海皓元医药股份有限公司	一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
TW201837026A (zh)	2017-01-10	2018-10-16	德商拜耳廠股份有限公司	作為除害劑之雜環衍生物（二）
EP4034101A1 (en) *	2019-09-25	2022-08-03	Goldfinch Bio, Inc.	Xanthine cb1 inhibitors
CN112724141A (zh) *	2021-01-21	2021-04-30	南京艾美斐生物医药科技有限公司	一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) *	2021-07-21	2021-09-17	北京矿冶研究总院	阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) *	2023-02-27	2025-09-18	Shanton Pharma Pte. Ltd.	Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2797220A (en) *	1954-12-02	1957-06-25	Univ Michigan	Substituted paraxanthines
US4847377A (en) *	1985-05-13	1989-07-11	Schering Corporation	Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) *	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
IL100088A (en)	1990-11-21	1995-07-31	Smithkline Beecham Corp	FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) *	1992-02-21	1993-09-13	Smithkline Beecham Corporation	TNF inhibitors
WO1993017684A2 (en)	1992-03-04	1993-09-16	Cell Therapeutics, Inc.	Enantiomeric hydroxylated xanthine compounds
US6469017B1 (en) *	1998-01-16	2002-10-22	Cell Therapeutics, Inc.	Method of inhibiting interleukin-12 signaling
US5804584A (en)	1992-11-16	1998-09-08	Cell Therapeutics, Inc.	Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) *	1992-11-16	2004-02-17	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US5473070A (en) *	1992-11-16	1995-12-05	Cell Therapeutics, Inc.	Substituted long chain alcohol xanthine compounds
IL109161A0 (en)	1993-03-31	1994-06-24	Cell Therapeutics Inc	Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en)	1993-04-05	1997-09-23	Cell Therapeutics, Inc.	Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en)	1993-04-09	1994-11-08	Cell Therapeutics, Inc.	Ring-substituted cell signaling inhibitors
WO1995020589A1 (en)	1994-01-28	1995-08-03	Cell Therapeutics, Inc.	Cell signaling inhibitors
US6103730A (en) *	1994-03-24	2000-08-15	Cell Therapeutics, Inc.	Amine substituted compounds
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en)	1994-02-18	2004-08-24	Cell Therapeutics, Inc.	Compounds having selective hydrolytic potentials
CA2183562A1 (en) *	1994-02-18	1995-08-24	J. Peter Klein	Intracellular signalling mediators
US5807861A (en) *	1994-03-24	1998-09-15	Cell Therapeutics, Inc.	Amine substituted xanthinyl compounds
US5801182A (en)	1994-03-24	1998-09-01	Cell Therapeutics, Inc.	Amine substituted compounds
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) *	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2369981A1 (en)	1999-04-09	2000-10-19	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
US20030207901A1 (en) *	1999-07-27	2003-11-06	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
HK1049835B (zh) *	1999-08-31	2005-04-08	范德比尔特大学	A2b腺苷受体的选择性拮抗剂
US6855817B2 (en) *	2000-07-21	2005-02-15	Mark B. Lyles	Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) *	2000-07-28	2003-01-24	Inside Technologies	Dispositif electronique portable comprenant plusieurs circuits integres sans contact
WO2002024194A2 (en) *	2000-09-19	2002-03-28	Novimmune S.A.	Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
MXPA03007349A (es)	2001-02-24	2003-12-04	Boehringer Ingelheim Pharma	Derivados de xantina, su preparacion y su empleo como medicamentos.
AU2002242910A1 (en) *	2001-04-11	2002-10-28	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
US7713982B2 (en)	2004-02-14	2010-05-11	Smithkline Beecham Corporation	Xanthines with HM74A receptor activity
WO2006045564A1 (en)	2004-10-22	2006-05-04	Smithkline Beecham Corporation	Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) *	2004-10-22	2009-08-20	Richard Jonathan Daniel Hatley	Xanthine Derivatives with HM74A Receptor Activity
MX2008001931A (es) *	2005-08-10	2008-03-24	Smithkline Beecham Corp	Derivados de xantina como agonistas selectivos de hm74a.
EP1939197A1 (en) *	2006-12-22	2008-07-02	Schwarz Pharma Ag	8-ethinylxanthine derivatives as selective A2A receptor antagonists
BRPI0922134A2 (pt) *	2008-12-08	2015-08-18	Glaxosmithkline Llc	Compostos
US20110065676A1 (en) *	2009-06-24	2011-03-17	Schering Corporation	Combination therapies comprising par1 antagonists with nar agonists

2005
- 2005-02-10 US US10/589,474 patent/US7713982B2/en not_active Expired - Fee Related
- 2005-02-10 JP JP2006552565A patent/JP5001012B2/ja not_active Expired - Fee Related
- 2005-02-10 CN CN2010102007350A patent/CN101863888B/zh not_active Expired - Fee Related
- 2005-02-10 PT PT57073637T patent/PT1781657E/pt unknown
- 2005-02-10 EP EP05707363A patent/EP1781657B1/en not_active Expired - Lifetime
- 2005-02-10 SI SI200531730T patent/SI1781657T1/sl unknown
- 2005-02-10 AU AU2005212816A patent/AU2005212816C1/en not_active Ceased
- 2005-02-10 CN CN2005800114336A patent/CN101103030B/zh not_active Expired - Fee Related
- 2005-02-10 HR HRP20130406TT patent/HRP20130406T1/hr unknown
- 2005-02-10 CA CA2556073A patent/CA2556073C/en not_active Expired - Fee Related
- 2005-02-10 WO PCT/EP2005/001449 patent/WO2005077950A2/en not_active Ceased
- 2005-02-10 SG SG200803771-5A patent/SG157242A1/en unknown
- 2005-02-10 PL PL05707363T patent/PL1781657T3/pl unknown
- 2005-02-10 BR BRPI0507604-8A patent/BRPI0507604A/pt not_active Application Discontinuation
- 2005-02-10 NZ NZ548496A patent/NZ548496A/en not_active IP Right Cessation
- 2005-02-10 ES ES05707363T patent/ES2406732T3/es not_active Expired - Lifetime
- 2005-02-10 KR KR1020067016277A patent/KR101100601B1/ko not_active Expired - Fee Related
- 2005-02-10 DK DK05707363.7T patent/DK1781657T3/da active
- 2005-02-11 PE PE2005000170A patent/PE20060317A1/es not_active Application Discontinuation
- 2005-02-14 MY MYPI20050527A patent/MY148937A/en unknown
- 2005-02-14 AR ARP050100512A patent/AR047669A1/es not_active Application Discontinuation
- 2005-02-14 TW TW094104133A patent/TWI350289B/zh not_active IP Right Cessation
2006
- 2006-07-24 IL IL177051A patent/IL177051A/en not_active IP Right Cessation
- 2006-08-11 MA MA29262A patent/MA28357A1/fr unknown
- 2006-09-13 NO NO20064151A patent/NO337281B1/no not_active IP Right Cessation
2008
- 2008-02-12 JP JP2008030344A patent/JP5020848B2/ja not_active Expired - Fee Related
2009
- 2009-09-02 US US12/552,649 patent/US8394808B2/en not_active Expired - Fee Related
2010
- 2010-03-04 US US12/717,349 patent/US8268839B2/en not_active Expired - Fee Related
2013
- 2013-02-06 US US13/760,423 patent/US20130150383A1/en not_active Abandoned
- 2013-05-29 CY CY20131100430T patent/CY1114022T1/el unknown
2014
- 2014-11-21 US US14/549,721 patent/US20150080418A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR047669A1 (es)	2006-02-01
MA28357A1 (fr)	2006-12-01
PL1781657T3 (pl)	2013-08-30
NO20064151L (no)	2006-11-06
PE20060317A1 (es)	2006-06-22
US8268839B2 (en)	2012-09-18
CA2556073A1 (en)	2005-08-25
HK1104530A1 (zh)	2008-01-18
US20130150383A1 (en)	2013-06-13
CA2556073C (en)	2012-01-10
DK1781657T3 (da)	2013-06-10
US20100010021A1 (en)	2010-01-14
CN101863888A (zh)	2010-10-20
HRP20130406T1 (hr)	2013-06-30
US7713982B2 (en)	2010-05-11
AU2005212816B2 (en)	2009-07-23
JP5001012B2 (ja)	2012-08-15
IL177051A0 (en)	2006-12-10
JP5020848B2 (ja)	2012-09-05
WO2005077950A3 (en)	2007-04-19
ES2406732T3 (es)	2013-06-07
SG157242A1 (en)	2009-12-29
TW200536537A (en)	2005-11-16
AU2005212816C1 (en)	2010-03-04
JP2007522176A (ja)	2007-08-09
NO337281B1 (no)	2016-02-29
CN101103030A (zh)	2008-01-09
CN101103030B (zh)	2010-10-13
WO2005077950A2 (en)	2005-08-25
AU2005212816A1 (en)	2005-08-25
US20150080418A1 (en)	2015-03-19
BRPI0507604A (pt)	2007-07-03
CY1114022T1 (el)	2016-07-27
US20070135456A1 (en)	2007-06-14
KR20060126772A (ko)	2006-12-08
KR101100601B1 (ko)	2011-12-29
EP1781657B1 (en)	2013-03-27
PT1781657E (pt)	2013-05-23
SI1781657T1 (sl)	2013-07-31
CN101863888B (zh)	2012-07-18
IL177051A (en)	2013-01-31
JP2008120831A (ja)	2008-05-29
US8394808B2 (en)	2013-03-12
US20100160354A1 (en)	2010-06-24
MY148937A (en)	2013-06-14
NZ548496A (en)	2010-02-26
EP1781657A2 (en)	2007-05-09

Publication	Publication Date	Title
GB0400812D0 (en)	2004-02-18	Novel compounds
GB0409744D0 (en)	2004-06-09	Novel compounds
EP1718638A4 (en)	2009-04-22	NEW COMPOUNDS
GB0405628D0 (en)	2004-04-21	Novel compounds
GB0402140D0 (en)	2004-03-03	Novel compounds
GB0402496D0 (en)	2004-03-10	Novel compounds
GB0402357D0 (en)	2004-03-10	Novel compounds
EP1805132A4 (en)	2010-01-20	NEW COMPOUNDS
GB0408083D0 (en)	2004-05-12	Novel compounds
EP1796793A4 (en)	2009-08-05	NEW CONNECTIONS
GB0402812D0 (en)	2004-03-10	Novel compounds
GB0402355D0 (en)	2004-03-10	Novel compounds
GB0402356D0 (en)	2004-03-10	Novel compounds
GB0404105D0 (en)	2004-03-31	Novel compounds
GB0402380D0 (en)	2004-03-10	Novel compounds
GB0402114D0 (en)	2004-03-03	Novel compounds
GB0400461D0 (en)	2004-02-11	Novel compounds
GB0402144D0 (en)	2004-03-03	Novel compounds
GB0402145D0 (en)	2004-03-03	Novel compounds
GB0402134D0 (en)	2004-03-03	Novel compounds
GB0402115D0 (en)	2004-03-03	Novel compounds
GB0402110D0 (en)	2004-03-03	Novel compounds
GB0401727D0 (en)	2004-03-03	Novel compounds
GB0400901D0 (en)	2004-02-18	Novel compounds
GB0400885D0 (en)	2004-02-18	Novel compounds

Legal Events

Date	Code	Title	Description
2019-07-11	MM4A	Annulment or lapse of patent due to non-payment of fees